Podium to Practice: EHA 2026 – Leukemia: LDAC Addition to Ven/Aza in AML

Podium to Practice: EHA 2026 – Leukemia: LDAC Addition to Ven/Aza in AML

Podium to Practice: EHA 2026

Studies / Trials Discussed

S125 – LOW-DOSE CYTARABINE AND VENETOCLAX PLUS AZACITIDINE COMPARED WITH VENETOCLAX PLUS AZACITIDINE IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A MULTICENTER RANDOMIZED PHASE III TRIAL

Icon Chair Speaker

Chair

Dr. Brett Houston

Icon Chair Speaker

Speakers

Dr. Christopher Hillis

Dr. Sonia Cerquozzi

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

S125 – LOW-DOSE CYTARABINE AND VENETOCLAX PLUS AZACITIDINE COMPARED WITH VENETOCLAX PLUS AZACITIDINE IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A MULTICENTER RANDOMIZED PHASE III TRIAL
Tagged